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AN INTRODUCTION TO URINARY 
TRACT INFECTION AND BLADDER 
BARRIER DEFENCES
Urinary tract infections (UTI) are among the leading causes 
of bacterial infections, worldwide, affecting nearly 150 mil-
lion people [1]. Whereas UTI incidence steadily increases 
with age in men and decreases in postmenopausal women, 
the highest infection frequency peaks among women aged 
between 15 and 29 years [2]. In fact, UTI are about 40 times 
more prevalent in women than in men among adults under the 
age of 60, and the proportion of individuals with UTI, annu-
ally, is four to five times higher among women than among 
men in the United States [2]. This difference in incidence is 
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Abstract
Urinary tract infections (UTI) are among the most prevalent infectious diseases and 
the most common cause of nosocomial infections, worldwide. Uropathogenic E.  coli 
(UPEC) are responsible for approximately 80% of all UTI, which most commonly af-
fect the bladder. UPEC colonize the urinary tract by ascension of the urethra, followed 
by cell invasion, and proliferation inside and outside urothelial cells, thereby causing 
symptomatic infections and quiescent intracellular reservoirs that may lead to recur-
rence. Sugars, or glycans, are key molecules for host– pathogen interactions, and UTI 
are no exception. Surface glycans regulate many of the events associated with UPEC 
adhesion and infection, as well as induction of the host immune response. While the 
bacterial protein FimH binds mannose- containing host glycoproteins to initiate infection 
and UPEC- secreted polysaccharides block immune mechanisms to favour intracellular 
replication, host glycans on the urothelial surface and on secreted glycoproteins prevent 
or limit infection by inhibiting UPEC adhesion. Given the importance of glycans during 
UTI, here we review the glycobiology of UPEC infection to highlight fundamental sugar- 
mediated processes of immunological interest for their potential clinical applications. 
Interdisciplinary approaches incorporating glycomics and infection biology may help to 
develop novel non- antibiotic- based therapeutic strategies for bacterial infections as the 
spread of antimicrobial- resistant uropathogens is currently threatening modern health-
care systems.
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less apparent in infants, children and the elderly, due in part to 
sex- dependent factors, such as hormones, which impact host 
defences [3,4]. The main risk factors for community- acquired 
UTI are biological sex, age and history of UTI, whereas cath-
eterization is the primary risk factor for healthcare- associated 
UTI [5,6].
The most prevalent pathogens of the urinary tract are 
Gram- negative or Gram- positive bacteria, collectively 
termed uropathogens [5,6]. Accounting for about 80% of 
reported UTI, uropathogenic E. coli (UPEC) are the princi-
pal infectious agents of the urinary tract [5,6]. Nonetheless, 
some fungi, such as Candida species, can proliferate in the 
genitourinary tract of patients with underlying urogenital ab-
normalities or indwelling catheters [5]. In addition, normally 
latent viruses, such as adenoviruses or human polyomavirus, 
may also colonize the lower urinary tract, potentially causing 
haemorrhagic cystitis in at- risk patients, such as immuno-
compromised children who have undergone allogeneic bone 
marrow transplantation [7].
Uropathogens can colonize the gastrointestinal tract as 
commensal bacteria, which may be a relevant reservoir for 
infection [5]. UPEC may spread among people through in-
dividual behaviours and close human relationships, such as 
cohabitation or sexual intercourse [8– 11]. From the periure-
thral area, uropathogens ascend the urethra to the bladder to 
establish infection [5]. Ultimately, bacterial ascension via the 
ureters leads to kidney colonization, or pyelonephritis, which 
increases the risk of bloodstream infection [5,12]. In men, 
prostate infection frequently accompanies cystitis, support-
ing the case for bacterial prostatitis to be classified as a UTI 
[13,14].
Urinary tract infections most frequently affect the blad-
der, despite the virtual impenetrability of the urothelium 
barrier system [15]. The luminal surface of the bladder is 
covered with uroplakin (UP) plaques, rendering it imper-
meable to non- gaseous molecules and resistant to the me-
chanical stresses associated with expansion and contraction 
of the organ [16]. UPs are integral membrane glycoproteins 
that assemble first as heterodimers of UP1a/UPII and UP1b/
UPIIIa and then come together to form the inner and outer 
domains of rosette- shaped plaques [17]. UPs are integrated 
into the apical membrane leaflet of hexagonally shaped um-
brella or facet cells, which constitute the luminal- facing layer 
of the urothelium [18]. Umbrella cells allow the bladder to 
accommodate variable urine volumes and maintain barrier 
integrity by reorganizing apical junctional rings, cytoskele-
ton and surface area, via Rab GTPase- dependent exocytosis 
or endocytosis of a subapical reservoir of discoidal- and/or 
fusiform- shaped vesicles [19– 23]. In addition to UPs, proteo-
glycans and membrane- tethered or secreted glycosaminogly-
cans (GAG) form a mucus layer that shields the urothelium 
from pathogens or harmful chemicals in urine [24]. The urine 
itself is integral to the bladder barrier because it protects the 
urothelium by flushing away metabolic waste and microbes. 
Urine also contains high concentrations of antimicrobial 
peptides, such as cathelicidin or lactoferrin, and opsonizing 
glycoproteins, such as antibodies or Tamm– Horsfall protein 
(THP or uromodulin), which can destroy uropathogens and 
block adhesion, respectively [25– 27].
Glycoproteins, proteoglycans and GAG are present on 
outer membranes of cells as part of the cellular interface with 
the extracellular space [28]. The polysaccharide groups on 
these macromolecules, called glycans, are the master regu-
lators of cell– cell interactions given their outermost location 
on cell surfaces [28]. Pathogenic bacteria, including UPEC, 
can bind tissue- or cell- specific glycoconjugates, supporting 
adhesion to host cells and playing a key role in determining 
pathogen tropism [29]. To resist urine flow and colonize the 
bladder, UPEC adhere to the urothelium via bacterial sur-
face appendages, called pili or fimbriae [30]. Attachment to 
specific host glycans occurs through adhesins, a family of 
carbohydrate- binding proteins located at the pili tip [30]. In 
addition to adhesion, pili- mediated binding of surface glycans 
initiates UPEC invasion of urothelial cells via a zippering 
mechanism involving close associations between the bacteria 
and the host cell surface [31,32]. Glycans also contribute to 
the process by which bacteria proliferate into large intracel-
lular bacterial communities (IBCs) protected by insulating 
capsular polysaccharides [29,30]. Host glycans present in the 
mucus layer, such as GAGs, and on the surface of secreted 
glycoproteins, such as THP, in turn, prevent bacterial attach-
ment to the urothelium and promote bacterial elimination in 
urine [33,34].
Here, we bring together experimental evidence describing 
how glycans mediate or prevent UPEC infection of the blad-
der, highlighting the relevance of glycan- dependent interac-
tions in UTI at different steps of the infection and immune 
response. Finally, we provide an updated view on the current 
state of sugar- based treatments for UTI as a valuable alter-
native to antibiotics in the wake of disseminated multidrug 
resistance.
CARBOHYDRATES DIRECTLY 
MEDIATE UPEC ATTACHMENT, 
INTERNALIZATION AND 
PROLIFERATION
UPEC interact with host glycans at very early stages of 
infection, in which the bacteria use filamentous adhesive 
organelles called type 1 pili to adhere to urothelial cells 
in the bladder [31,32,35,36]. The coiled polymeric struc-
ture found in these pili terminates at its distal tip with 
the adhesin FimH, which mediates binding of UPEC to 
the urothelium [37,38]. Type 1 pili or FimH mutants are 
unable to adhere to the urothelium in a mouse model of 
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cystitis or invade bladder cells in vitro [32,39]. FimH has 
two protein domains: the pilus- linking pilin domain and the 
distal lectin domain, which binds carbohydrates [38,40]. 
The FimH lectin domain binds terminal mannose(α1,3)- 
mannose residues with high affinity and, to a lesser extent, 
mannose(α1,2)- mannose and mannose (α1,6)- mannose 
[41,42]. These constitute the terminal moieties of high- 
mannose N- glycans, which are particularly abundant on 
UP1a and integrin α3β1 [36,43,44].
As UPs almost entirely cover the luminal surface of um-
brella cells, UP1a mannose groups are the most frequently en-
countered FimH receptor on the urothelium of many species, 
including humans, mice and cattle [15,36,43]. Interestingly, 
the presence of N- acetylglucosamine (GlcNAc), at the high- 
mannose core, increases FimH affinity towards mannosides 
[41]. Molecular docking models predict that the mannose(β1- 
4)- GlcNAc motif stabilizes the terminal mannose insertion 
in the cavity of the FimH mannose- binding pocket [41]. 
F I G U R E  1  Glycan- dependent interactions that promote or prevent infection in the urinary tract. Uropathogenic E. coli (UPEC) colonize the 
bladder by adhering to the urothelium via hair- like extracellular appendages called pili, which have carbohydrate- binding proteins at their tips. (a) 
The major facilitator of colonization is the adhesin FimH, which binds mannose moieties of high- mannose structures on uroplakins (UPs) covering 
urothelial cell membranes. In the bladder, mannose- specific FimH- mediated UPEC binding induces bacterial internalization into umbrella cells 
via endocytosis into discoidal/fusiform vesicles. Internalized UPEC escape into the cytoplasm, where they aggregate and rapidly proliferate to 
form densely packed intracellular bacterial communities (IBCs). Extracellular bacterial polysaccharides, such as the K1 capsule, contribute to the 
formation, shape, and growth of IBCs. (b) UPEC can also ascend the ureters to the kidneys to cause pyelonephritis by invading and proliferating 
in renal tubular epithelial cells. To adhere to the kidney epithelium, UPEC typically use the galactose- specific PapG adhesins on P pili, which 
bind galactose- rich membrane glycolipids, including globotetraosylceramides and globotriaosylceramides. (c) Host glycans can prevent UPEC 
adhesion to the urothelium. Glycosaminoglycan (GAG)- rich proteoglycans form a gel- like mucus layer on the luminal surface of the bladder, 
which blocks FimH- mediated binding to mannosylated glycoproteins on the urothelium, inhibiting invasion of urothelial cells. In the lumen, highly 
glycosylated Tamm– Horsfall protein (THP) has uroplakin- like mannose glycans, which bind FimH with high affinity, preventing UPEC adhesion. 
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Considering that FimH preferentially binds terminally ex-
posed mannoses [43], these results suggest that interactions 
with the N- glycan core of high- mannose glycans may stabi-
lize FimH binding. Nevertheless, whether UPEC shows dif-
ferential affinity towards terminal or core mannoses during 
UTI remains to be established.
After binding, FimH minimizes the probability of UPEC 
expulsion during micturition by enhancing its mannose- 
binding strength via a catch- bond mechanism, whereby the 
binding pocket affinity for mannosylated structures increases 
under the tensile mechanical force exerted by urine flow 
[45,46]. Given the prevalence of UPEC- mediated UTI, the 
abundance of UP on the urothelium and the requirement of 
FimH- mediated UPEC adhesion to initiate UTI, binding of 
FimH to mannose groups of UP1a exemplifies a key glycan 
target to disrupt host– pathogen interactions (Figure 1a).
Tissue glycosylation can vary over disease progression or 
following environmental changes, such as diet, smoking or 
age. It is therefore relevant to ask whether interindividual dif-
ferences or long- lasting changes in urothelial glycosylation 
may differentially contribute to the risk of UTI. Interestingly, 
galactosyltransferase expression is upregulated in mouse 
bladders in UTI, and UPEC increase the expression of Fml 
pili with its associated FimH- like FmlH adhesin, which has 
high affinity for galactose- containing epitopes in chronic UTI 
models [47]. Microscopic analysis with fluorescence- tagged 
FmlH stains the GalNAc- rich intermediate urothelial layer of 
mouse bladders only in chronically infected mice, whereas 
staining in naïve bladders is scattered [47]. As exfoliation 
of bladder apical cells exposes the underlying intermediate 
urothelium, this observation suggests that the FmlH adhesin 
may help UPEC to resist elimination in urine by binding to 
the intermediate urothelium surface later in infection.
Once UPEC access the bladder, FimH- mediated bind-
ing to terminal mannoses on host UP or integrin α3β1 in-
duces UPEC engulfment by umbrella cells [31,32,44,48]. 
Cross- linking of other FimH membrane receptors (reviewed 
elsewhere [30]) on adjacent lipid rafts activates down-
stream signalling pathways, such as Rho family GTPases, 
leading to actin cytoskeleton reorganization and UPEC en-
docytosis via intracellular trafficking proteins, such as dy-
namins [31,32,49]. The plasma membrane zippers around 
attached pili, facilitating the intimate binding of UPEC to 
the urothelium by engaging other coreceptors in lipid rafts 
[32,44,49,50]. Upon entry, some UPEC escape into the cyto-
plasm and proliferate rapidly to form clonal IBCs, which are 
biofilm- like, intracytoplasmic masses of bacteria that assume 
a coccoid shape [51– 55]. A small number of UPEC may also 
invade intermediate cells and persist in late endosomal vesi-
cles surrounded by a ‘cocoon’ of actin filaments, as quiescent 
intracellular reservoirs over periods of time [51,53,56].
UPEC induce host cell defence mechanisms arising from 
host recognition of pathogen- associated molecular patterns, 
such as lipopolysaccharides, or other bacterial factors not yet 
identified [48,57]. For example, FimH- mediated bacterial 
adhesion to mannosylated sites on umbrella cell membranes 
induces caspase- dependent apoptosis and exfoliation of these 
cells, leading to elimination of IBCs [31,48]. Additionally, 
umbrella cells can expel invading bacteria before IBC for-
mation. UPEC hijack the bladder cell trafficking machinery 
to enter via Rab11b/Rab27b+ cAMP- responsive fusiform 
vesicles; however, binding of intracellular TLR4 in infected 
urothelial cells induces exocytosis of UPEC- containing vac-
uoles via similar Rab27b+ cAMP- dependent pathways, thus 
reducing the number of intracellularly proliferating bacteria 
[58– 60].
Interestingly, UPEC require FimH not only for binding 
of mannosylated host surface proteins and cell invasion, but 
also for intracellular survival and proliferation into IBCs 
[39,61]. In a mouse model of UTI, UPEC mutants that do 
not express type 1 pili during the intracellular phase are de-
creased in number and do not organize into IBCs compared 
with infection with the control parental strain, demonstrat-
ing that type 1 pili aid formation of IBCs [39]. FimH spe-
cifically facilitates IBC development as mutations in two 
positively selected residues of the FimH pilin domain are 
sufficient to reduce IBCs in mice compared with animals 
infected with the wild- type isogenic UPEC strain [61]. 
Strikingly, the fitness reduction in UPEC mutants is spe-
cific to the urinary tract, as gut colonization is comparable 
to wild- type strain, and is apparent only at later time- points 
after initial intracellular colonization, when IBC develop-
ment has already begun [61]. This is because positively se-
lected residues of the pilin domain affecting the aggregation 
of intracellular UPEC into IBCs do not impair the mannose- 
binding capacity of FimH required for UPEC adhesion or 
invasion [61].
UPEC not only recognize host glycans, but they also 
synthesize their own set of carbohydrates to promote intra-
cellular proliferation into IBCs [30] (Figure 1a). To limit 
their detection and favour proliferation, internalized UPEC 
secrete a protective polysaccharide- rich matrix that can in-
corporate host membrane- derived UPs [52]. The bacterial 
polysaccharide layer is poorly immunogenic and, as such, 
hides immunogenic molecular patterns from host intracellu-
lar recognition receptors [62]. In this way, IBC development 
may delay immune responses, such as caspase- 3- mediated 
exfoliation of umbrella cells or phagocytosis [31,63]. As 
E. coli strains secrete multiple types of surface- enveloping or 
capsular extracellular polysaccharides, identifying the exact 
biochemical composition of the polysaccharide- rich matrix 
produced by intracellular UPEC at different time- points 
during UTI, including during formation of IBCs, will be 
challenging [53,62].
Most UPEC isolates produce capsular polysaccharides, 
such as the polysialic acid K1 capsule, and other negatively 
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charged polysaccharides that may polymerize into biofilm- 
like structures, such as colanic acid, β- 1,6- N- acetyl- D- 
glucosamine or cellulose [62]. Specifically, K1 capsule and 
associated sialic acid signalling mediate a crucial structural 
role during intracellular proliferation in UTI [63]. Many 
IBC- forming UPEC strains express K1 polysaccharides in 
vivo, and deficiencies in K1 capsule synthesis or assembly, 
compromising capsule production, result in comparably re-
duced bacterial counts in mice 2 weeks post- infection [63]. 
K1- deficient UPEC numbers also decrease more quickly 
over time in mice than bacterial CFU of a cystitis patient- 
derived UPEC strain [63]. Similar to the type 1 pili or FimH 
pilin domain mutants [53,61], the numbers of intracellular 
K1 capsule- deficient UPEC bacteria are decreased because 
they fail to aggregate into IBCs. In fact, K1 capsule- deficient 
UPEC mutants further altered to upregulate sialic acid traf-
ficking and metabolism display partially restored capacities 
of K1 capsule synthesis and IBC development compared with 
K1 capsule- deficient single- mutant strains, showing that se-
creted polymeric glycans facilitate UPEC proliferation into 
IBCs [63]. However, the exaggerated catabolism and dysreg-
ulated sensing of intracellular sialic acid in the UPEC double 
mutants used in this study may have decreased intracellular 
concentrations of sialic acids, such as N- acetylneuraminic 
acid (Neu5Ac) or N- acetylglucosamine (GlcNAc) [63], which 
would normally downregulate the OFF- to- ON phase varia-
tion switch that selectively induces type 1 pili expression in 
UPEC during UTI [64– 67]. Therefore, it needs to be veri-
fied whether the partial restoration of IBC development 
capacity in these mutant UPEC is directly dependent on cap-
sular polysaccharide metabolism rather than increased sur-
face expression of type 1 pili. Future studies of the secreted 
polysaccharides of UPEC should also include investigation 
of their potential signalling functions to elucidate whether 
these bacterial glycans inhibit intracellular immune response 
mechanisms.
GLYCOLIPIDS SERVE AS 
SCAFFOLDS AND FOOTHOLDS FOR 
UPEC
Glycans are also attached to lipids on cell surfaces, creating a 
rich diversity of glycolipid structures. In the urothelium, gly-
colipids maintain the steep osmotic gradient between urine 
and plasma [15]. Biochemical and chromatographic studies 
of the bladder show that the luminal plasma membrane is 
made primarily of ceramides, which are glycosphingolip-
ids consisting of a sphingosine backbone, one fatty acid tail 
and a polar head made of the monosaccharides D- glucose or 
D- galactose [68,69]. Umbrella cell membranes have a non- 
symmetrical ceramide distribution, with higher expression 
in the apical leaflet of the lipid bilayer compared with the 
cytoplasmic side [68]. In addition to reduced permeability 
compared with phospholipids, the height of the ceramides 
and of the embedded uroplakins is very similar, enhancing 
the structural stability of UP in umbrella cell membranes 
[70]. Although glycolipids constitute 62% of the plaque 
three- dimensional structure, including the hollow centre with 
the FimH- targeted high- mannose structures [70], the bacte-
rial factors governing UPEC interaction with bladder gly-
cosphingolipids during UTI remain unknown.
Glycolipids play an important role when bacteria reach 
the kidneys, where UPEC preferentially bind to the galac-
tose moieties of globotetraosylceramides (Gb4Cer) and 
globotriaosylceramides (Gb3Cer), two classes of ceramides 
bearing a combination of N- acetylgalactosamine, D- glucose, 
and D- galactose, which are highly expressed in the kidneys 
[69,71,72]. To mediate binding, UPEC use the attachment 
appendages called P pili. These are heteropolymeric fibres 
capped by the PapG adhesion molecule, which has high af-
finity for galactose(αl- 4)galactose epitopes, such as those 
found in Gb4Cer and Gb3Cer [72,73]. Thus, UPEC strains 
that express P pili can bind the kidney tubular papillary ep-
ithelium and cause pyelonephritis [73] (Figure 1b). Similar 
analyses in umbrella cells will help to determine whether 
UPEC require the binding of specific membrane glycolipids 
after FimH- mediated adhesion to facilitate the engagement of 
lipid rafts initiating cell invasion.
BLADDER GLYCOSAMINOGLYCANS 
PREVENT UPEC ADHESION
As an added layer of complexity in the glycobiology of the 
bladder barrier, the urothelium is physically separated from 
harmful metabolites or invading uropathogens by a protec-
tive layer of secreted or membrane- tethered GAGs, as well 
as proteoglycans, which are linearized proteins decorated 
with a high number of different GAGs [24]. GAGs are 
long, negatively charged linear polysaccharides formed by 
polymerization of repeating disaccharide monomers made 
of amino sugars, such as sialic acids (N- acetylneuraminic 
acid [Neu5Ac] in humans), and a galactose or an oxidized 
monosaccharide, such as D- glucuronic acid [74]. Heparan 
sulphate (54%), chondroitin sulphate (29%) and dermatan 
sulphate (17%) are the most common GAGs in the human 
bladder [74]. In all cases, the long sugar chains in GAGs and 
proteoglycans give these molecules the capacity to strongly 
bind water molecules via intermolecular forces, thus trap-
ping them into a gel- like structure that separates the bladder 
urothelium from urine and non- gaseous molecules.
GAG concentration in human urine samples or from pig 
bladder scrapings suggests that the mucus lining the bladder 
is thin and largely made of proteoglycans [75]. The bladder 
GAG layer is about 10 times thinner than the mucus in the 
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mouse colon [76], supporting the idea that the bladder sur-
face requires different protection compared with the intes-
tine. Bladder tissue is not absorptive like the gut and instead 
prevents the entry of non- gaseous material from the lumen 
through cell– cell junctional rings and surface UP [15,68]. 
Beyond the intrinsically different functions and structures 
of the bladder and gut, the presence of different numbers 
and types of commensal bacteria or metabolites likely re-
quires different barriers in the two mucosal tissues [15,77]. 
Additionally, copious mucus secretion may pose an obstacle 
to urination.
However thin, the bladder mucus prevents bacterial adhe-
sion to urothelium [78] (Figure 1c). Non- specific or GAG- 
specific chemically mediated depletion of the bladder mucus 
layer leads to increased attachment of radioactively labelled 
UPEC, Klebsiella pneumoniae or Staphylococcus aureus in a 
rabbit model, supporting that bladder mucus impedes adher-
ence to the urothelium [78– 80]. Interestingly, observation via 
scanning and transmission electron microscopy of bladder 
mucus in a rat model of UTI with UPEC shows a membrane- 
bound layer of hair- like GAGs entrapping large microcolonies 
of bacteria surrounded by a glycocalyx [81]. These micro-
graphs support the idea that to reach mannosylated glyco-
proteins on umbrella cell surfaces with their pili, UPEC may 
adhere to and burrow through the mucus polymers. Although 
bladder mucus degradation by UPEC has never been formally 
demonstrated and no pathogenic K1 serotypes of extraintes-
tinal E. coli express specific glycosaminolytic enzymes [82], 
UPEC may penetrate the GAG layer by secretion of serine 
protease autotransporters of Enterobacteriaceae (SPATE). 
Some SPATE, such as Pic, display dose- dependent glycos-
aminolytic activity in vitro [83]. However, mice inoculated 
with a pyelonephritis patient- derived UPEC strain or a Pic- 
deficient mutant show similar bacterial burden in bladder and 
kidneys 6 days post- infection, suggesting that Pic deficiency 
does not impair UPEC fitness in vivo [84].
Urinary tract microbiota may also influence UPEC fitness 
during infection by mucus consumption [77]. As microbiota- 
liberated GAG carbohydrates regulate the growth of entero-
haemorrhagic E. coli in the intestine, the relative proportion 
of mucus- degrading bacteria species may favour UPEC 
infection by secretion of glycosaminolytic enzymes [85]. 
Oral administration of mucus- constituting glycans to mice 
tempers the detrimental perturbations of the gut microbial 
community by favouring the growth of mucus- consuming 
commensals that are prevalent in the healthy gut [86]. Given 
the differences between mucus layers of the gastrointestinal 
and urinary tract, it would be interesting to test whether mod-
ulating the relative abundance of urinary tract commensals 
feeding on bladder mucus impacts host susceptibility to UTI. 
Therefore, future studies should establish whether UPEC re-
quire the presence of a mucus- degrading commensal popula-
tion to bind urothelium, or whether SPATE or other unknown 
virulence factors permit UPEC to penetrate the host mucus to 
reach the urothelial surface.
TAMM– HORSFALL PROTEIN, 
A CRITICAL HOST DEFENCE 
MOLECULE
In addition to GAGs, non- glycosylated cationic antimicro-
bial peptides, such as β- defensins or cathelicidin, contribute 
to protection of the bladder urothelium against uropathogens 
and toxins [27]. The most abundant glycoprotein in urine 
is Tamm– Horsfall protein (THP also called uromodulin), 
which is constitutively secreted in the kidneys, specifically 
by the renal cells in the thick ascending limb of the loop of 
Henle [34]. In urine, THP forms large multimeric aggregates 
with a flexible zigzag- shaped backbone and protruding hair- 
like filaments that physically prevent UPEC interaction with 
the urothelium by entrapping bacteria and clumping them to-
gether with its highly glycosylated surface [87]. Each THP 
monomer contains mannosylated and sialylated N- glycans 
that may antagonize glycan– uropathogen interactions, act-
ing in urine as a multivalent molecular ‘decoy’ [87]. The 
high- mannose structures on the surface of THP strongly bind 
type 1- piliated UPEC in a mannose- dependent fashion, and 
THP deficiency results in greater bacterial numbers in mouse 
bladders, supporting that THP glycans are protective against 
UPEC infection in the bladder [88– 90] (Figure 1c). Light mi-
croscopy or cryoelectron tomography analysis of urine from 
UTI patients infected with several uropathogens, including 
UPEC, reveals multiple bacterial aggregates associated with 
and surrounded by THP filaments, which even display clear 
contacts with pilus tips [87]. Consequently, changes in the 
glycosylation of THP may make the human urinary tract 
more permissive to infection. For instance, patients with type 
I diabetes have lower amounts of sialic acid in urinary THP 
compared with healthy volunteers, which may contribute to 
the higher risk of UTI among diabetic patients [91].
In addition to type 1 pili and P pili, which are associated 
with UPEC infection of the bladder and kidneys, respectively, 
another type of filamentous adherence structure, called S 
pilus, mediates binding in the urinary tract [34,92]. Whereas 
type 1 and P pili recognize and bind mannose and galac-
tose disaccharides, respectively, S pili specifically adhere 
to sialic acids capping terminal galactosides [NeuAc(α2,3)
Gal], which are found in the branches or antennae of THP N- 
glycans [34]. Consequently, THP may be protective against 
kidney infections by S- piliated UPEC as renal luminal cells 
of the distal tubules are also enriched with surface oligo-
saccharides containing NeuAc(α2,3)Gal [34]. However, the 
protective role of THP against S- piliated UPEC needs veri-
fication because the binding of THP by the adhesin of S pili 
has not been experimentally demonstrated, and the functional 
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role of S pili during UTI remains unclear [92]. Interestingly, 
atomic force microscopy experiments with an S- piliated 
UPEC strain reveal that the helix- like structure of the S pili 
shaft has the most rapid relaxation kinetics compared with 
type 1 and P pili, indicating that when pili unravel to absorb 
shear stress forces, such as urine flow, S pili are the first to 
recover their initial quaternary structure [92]. A faster relax-
ation of the rod may reduce the load exerted on the apical 
adhesin, potentially extending the duration of adhesion to the 
sialic acid- rich urothelium of the upper urinary tract, thereby 
favouring the ascension of S- piliated UPEC to the kidneys. 
Therefore, future glycobiology studies are needed to test the 
putative protection provided by THP against infection with 
S- piliated UPEC strains in vivo, as well as determine bind-
ing properties and the role of the S pilus during bladder and 
kidney infections.
Infected mice lacking THP have not only increased 
bacterial counts in the urine and bladder, but also elevated 
mortality that may be due to an exaggerated inflammatory 
response [89,90]. Indeed, significantly increased neutrophil 
numbers are present in the urine of THP- null mice 24 h after 
instillation of PBS into the bladder [93]. Greater neutrophil 
infiltration may be attributable to THP glycans as the sur-
face cell protein sialic acid- binding immunoglobulin- type 
lectin- 9 (Siglec- 9, Siglec- E in mice) in human neutrophils di-
rectly binds to the structure Neu5Ac(α2,3)Gal(β1,4)GlcNAc 
on THP to decrease reactive oxygen species ex vivo [93]. 
These studies provide evidence to suggest that THP glycans 
not only directly protect against UTI as decoys for bacterial 
receptors, but may also regulate immunity to UTI by blunt-
ing the activation of infiltrating immune cells, such as neu-
trophils, where an exaggerated antimicrobial response may 
impair urothelial barrier integrity. Nonetheless, whether in-
hibition of neutrophil oxidative burst via THP- mediated en-
gagement of Siglec- 9/Siglec- E receptors has consequences 
on UTI needs to be verified in vivo. Altogether, the above 
studies highlight how integral THP is to bladder immunity 
and support a renewed translational research interest in THP 
glycosylation to explore its underappreciated barrier and im-
munomodulatory roles for clinical applications.
TRANSLATIONAL GLYCOBIOLOGY 
IN UTI: HOW TO SWEET TALK 
UPEC
More than 20 years ago, the finding that a FimH null mutant 
of UPEC had impaired colonization and induced less inflam-
mation in mouse bladders, together with the widespread ex-
pression of FimH in UPEC strains, supported the idea that 
a FimH- targeted vaccine may provide positive therapeutic 
outcomes [35,94,95]. While this idea has not entirely borne 
out, as these vaccines have only shown preclinical efficacy 
[95], understanding the glycobiology of UPEC infection and 
immunity may offer additional opportunities to target FimH 
and other glycan- dependent interactions in the clinic [96,97]. 
Administration of a mixture of selective sugar antagonists for 
UPEC adhesins via a catheter may be an inexpensive strat-
egy to significantly decrease the risk of developing UTI [98]. 
By passively targeting invading uropathogens, sugar- derived 
drugs or glycomimetics have the potential to treat UTI and 
prevent recurrence regardless of most host- dependent factors.
As the mannose- specific recognition of FimH adhesin is 
well established, and nearly all UPEC strains express type 
1 pili, many glycobiology studies focus on blocking this 
crucial interaction [41,96,99]. The earliest examples are 
soluble monosaccharides, such as D- mannose, which block 
lectin- mediated adhesion of uropathogens to urothelial cells 
in vitro [100]. Promisingly, daily oral intake of D- mannose 
supplements has the same efficacy as the antibiotic nitro-
furantoin in reducing the frequency of infection in women 
with recurrent UTI [101]. Addition of D- mannose to UPEC 
incubated with human THP did not alter UPEC association 
with THP filaments or THP- mediated UPEC clumping in 
vitro [87], suggesting that prophylactic administration of D- 
mannose to patients with recurrent UTI may synergize with 
urinary THP to antagonize UPEC adhesion. To further test 
its therapeutic potential, an ongoing double- blinded placebo- 
controlled clinical trial in the UK has recruited 598 women 
to test whether daily intake of D- mannose reduces the rate of 
UTI recurrence within a 6- month period [102].
Aromatic alpha- mannosides, molecules containing a 
mannose linked to a benzene group, are a promising alter-
native to D- mannose due to their comparatively increased 
affinity for the mannose- binding domain of FimH [96]. 
Rationally designed, high- affinity mannoside antagonists of 
FimH block UPEC adhesion to cognate urothelial carbohy-
drates, preventing UPEC invasion [97,98]. Oral treatment 
with the high- affinity FimH antagonist mannoside M4284 
reduces UPEC burden in the colon, bladder, and kidneys of 
mice intentionally colonized with UPEC in both the gut and 
urinary tract, compared with D- mannose control treatment 
[103]. This study demonstrates that mannosides not only treat 
UTI but may reduce the risk of new episodes by depleting 
tissue- associated UPEC reservoirs. Oral administration of a 
mannoside- containing compound to mice shortly before and 
after UPEC instillation, respectively mimicking prophylaxis 
and treatment, significantly reduces early colonization lev-
els in the bladder, demonstrating that sugar- derived drugs 
have the potential to treat UTI [98]. Mannoside antagonists 
further reduce bacterial numbers in mouse bladders when 
administered in combination with a standard antibiotic reg-
imen for UTI compared with either treatment alone, suggest-
ing that sugar- based drugs may enhance bacterial killing by 
UPEC sequestration in urine. Therefore, glycan- based drugs 
could reduce the use of antibiotics, which will be of utmost 
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importance as UPEC strains exhibit diverse and widespread 
antibiotic resistance [5].
Based on promising experimental and clinical evidence 
collected so far, sugar- based mannose- specific FimH antag-
onists may be a safe and inexpensive drug to treat cystitis. 
Although their efficacy may not be as potent as antibiotics, 
carbohydrate- based anti- adhesives are not expected to select 
for resistance genes or have detrimental side effects on the 
microbiota, thus arguing in favour of their use for treatment 
of UTI and prophylaxis against recurrence [104]. Overall, 
promoting the prophylactic use of effective antimicrobial 
glycan- based therapeutics as an alternative to antibiotics, as 
well as determining the consequences of their long- term use, 
could be an efficient approach to limit the impact of antimi-
crobial resistance.
Learning from the successful clinical translation of 
mannose- based therapeutics for treatment of cystitis, future 
glycobiology studies may consider whether galactose- rich 
bioactive compounds that target PapG adhesins and are re-
tained in the kidneys could inhibit the severity of pyelone-
phritis. For translational studies, some caution should be 
taken when using animal models. Basic glycosylation path-
ways are conserved in mammals, but some differences can 
be found between humans and common laboratory species. 
Understanding these structural differences in GAGs, gly-
coproteins, and glycolipids would facilitate the design of 
glycan- based drugs. Glycan structural complexity and diver-
sity are major obstacles for the translation of basic discov-
eries to glycan- based therapeutics. Structural analysis relies 
on mass spectrometry or nuclear magnetic resonance spec-
troscopy, which are time- consuming, expensive and require 
large amount of biological material. However, recent break-
throughs in the field [105], such as novel arraying methods 
and improved carbohydrate synthesis, may foster transla-
tional glycobiology in the next years.
FINAL REMARKS
In conclusion, carbohydrates play a prominent role in host 
invasion and response during UTI. Following UPEC infec-
tion, FimH- mediated mannose binding induces adhesion and 
invasion of the urothelium, which is aided by bacterial capsu-
lar polysaccharides. However, host GAGs and proteoglycans 
protect the urothelium from bacterial adhesion, thereby re-
ducing bacterial invasion. In addition, secreted, highly glyco-
sylated glycoproteins, such as THP, inhibit UPEC attachment 
by binding to FimH or other bacterial adhesion proteins to re-
duce bacterial burden. Lectin antagonists show encouraging 
results in the treatment of UTI, revealing a promising horizon 
for translational glycobiology and supporting that the investi-
gation of glycans involved in UTI will drive the discovery of 
targets for non- antibiotic therapies based on sugars.
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